# US 11,433,056 B1 · Methods of treating gastrointestinal stromal tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,433,056 B1
- Document ID: US11433056B1
- Status: Granted
- Kind: B1
- Application number: 17/735,862
- Filed: 2022-05-03
- Published: 2022-08-18
- Granted: 2022-09-06
- Earliest claimed: 2019-08-12
- Assignees: Deciphera Pharmaceuticals, LLC
- Applicants: Deciphera Pharmaceuticals, LLC
- Inventors: Rodrigo Ruiz Soto; Oliver Rosen; Jama Pitman
- Web page: https://patentgrep.com/patent/US11433056B1

## CPC

- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/12: Antihypertensives
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.

## Claims

### Claim 1

A method of treating a patient suffering from Grade 2 or Grade 3 myalgia while being administered 150 mg ripretinib daily for treatment of gastrointestinal stromal tumors, comprising:
withholding administration of ripretinib for at least 7 days or until the patient has less than or equal to Grade 1 myalgia then administering to the patient 100 mg daily ripretinib for at least 28 days, if the patient is suffering from Grade 3 myalgia;
or if the patient is suffering from Grade 2 myalgia, withholding administration of ripretinib until the patient has less than or equal to Grade 1 myalgia or baseline; if the patient recovers from the myalgia within 7 days of withholding administration, then administering to the patient 150 mg daily ripretinib, or if the patient has not recovered, then administering to the patient 100 mg daily ripretinib for at least 28 days.

### Claim 2

A method of treating a patient suffering from Grade 3 myalgia while being administered 150 mg ripretinib daily or twice daily for treatment of gastrointestinal stromal tumors, comprising withholding administration of ripretinib for at least 7 days or until the patient has less than or equal to Grade 1 myalgia, then administering to the patient 100 mg daily ripretinib for at least 28 days.

### Claim 3

A method of treating a patient suffering from Grade 2 myalgia while being administered 150 mg ripretinib daily for treatment of gastrointestinal stromal tumors comprising a) withholding administration of ripretinib until the patient has less than or equal to Grade 1 myalgia or baseline; b) if the patient recovers from the myalgia within 7 days of withholding administration, then administering to the patient 150 mg daily ripretinib or c) if the patient has not recovered, then administering to the patient 100 mg daily ripretinib for at least 28 days.